Table 2.
In Vivo Studies on Se Compounds Used in the Experimental Studies on Cervical Cancer.
| References | In vivo model | Se compound or Se containing product (dose, time of treatment) | The effect of Se | Mechanisms of action |
|---|---|---|---|---|
| Hussain and Rao, 1992 32 | MCA induced cervical cancer in mice | Sodium selenite 1 ppm exposure 1 week before and 12 weeks after MCA insertion |
Decreased tumor incidence | Not studied |
| Guo et al, 2013 22 | HeLa injected BALB/c mice | Sucrose Se ester 1, 2, 4, 8 mg/kg/day 7 days |
Increased survival time 0.75, 1.06, 1.67, and 0.50 for doses 1, 2, 4, and 8 mg/kg, respectively |
Not studied |
| Xia et al, 2020a 29 | HeLa injected BALB/c mice | Se-NPs modified with HA and drug (DOX) 2 mg/kg DOX 21 days | supressed tumor growth | Inhibition of cancer cells proliferation (as shown by decreased expression of Ki67 protein); induction of apoptosis |
| Li et al, 2016 30 | HeLa injected BALB/c mice | Bi2Se3NPs modified with drug (DOX) 0.81 mg/kg DOX and 25 mg/kg Bi2Se3
12 days additional combination with 10 min irradiation |
Tumor growth inhibition maintained also after the therapy | Not studied |
| Xia et al, 2020b 31 | HeLa injected BALB/c mice | Se-NPs combined with arginylglycylaspartic acid peptide and Derlin1-siRNA 0.2 mg/kg of the eqivalent siRNA per day, 21 days | Decreased tumor volume; no toxicity observed in heart, liver, spleen, lung, and kidney | Apoptosis; increased expression of pp53, caspase-3 and Bak |
| Ji et al, 2014 33 | MCA induced cervical cancer in mice | Sodium selenite enriched mushrooms (Se-CS) Se content in mycella: 4789 µg/g, daily dose not known, 90 days | Decreased tumor incidence by 40% | Improved immune function (as shown by alleviation of MCA induced decrease of thymus and spleen); decreased oxidative stress |
| Zhang et al, 2012 34 | MCA induced cervical cancer in mice | Aqueous suspension of pulverized mace of Myristica fragrans Houtt 10 mg of mace/day 90 days | Decreased tumor incidence from 100% to 10% | Not studied |
Abbreviations: Bak, Bcl-2 homologous antagonist/killer; DOX, doxorubicin; HA, hyaluronic acid; MCA, 3-methylcholanthrene; SE-NPs, selenium nanoparticles.